Revista Practica Medicala, Vol. XI, Nr. 4 (48), 2016
ISSN 1842-8258  |  e-ISSN 2069-6108
ISSN-L 1842-8258

Indexed in / abstracted by

Thomson Reuters Embase
Scopus Cross-ref
Index Copernicus
Ulrichs Ebsco Host
Medline - Ebsco PubMed


Publicarea de articole stiintifice

Stimati cititori, va reamintim ca autorii primi ai articolelor stiintifice pot acumula 80 de credite EMC in urma publicarii. Daca un articol are mai multi autori, cele 80 de credite [...]

Premiul Societatii pentru autori

Incepand cu 2016, Societatea Academica de Medicina a Familiei ofera Premiul Societatii - pentru autorii celor mai bune articole stiintifice publicate [...]

Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

Teriparatide as option for severe osteoporosis

, , and

We introduce an original study referring to Romanian population treated with teriparatide (TPT), an anabolic drug for severe menopausal, glucocorticoid and male hypogonadism-related osteoporosis. Primary end point is to analyze the parameters of persons who fulfilled the national criteria of TPT regarding co-morbidities and bone profile. Secondary end point is to reveal the skeleton indices 12 months after TPT (20 μg/day subcutaneous). Informed written consent was signed between July 2015 and June 2016. Out of 21 patients with a mean age of 66.76 years (yrs), except for 2 men, there were menopausal females with av. 21.47 yrs since menopause. 57% had a history of superior digestive condition, another 57% had a chronic thyroid disease and 29% had a non-thyroid autoimmune morbidity. 17 patients were pre-exposed to anti-osteoporotic drugs 4.23+/-3.49 yrs. Number of prevalent fractures was: 3.75+/-2.17 (median 3; min 1, max 9). 42% (N=9) of subjects were followed for 1 year: no new fracture was registered; each patient had at least one DXA site with a BMD (Bone Mineral Density) increase (mean T-score increase of the most affected region was of 0.56+/-0.2 SD); osteocalcin statistically significant elevated from 18.87+/4.22 ng/mL to 42.8+/-16.3 ng/mL (p<0.0005) while CrossLaps went from 0.46+/-0.22 ng/mL to 0.65+/-0.3 ng/mL (p=0.15). Early drop-offs were registered in 2 patients.
Based on this original study, patients with severe osteoporosis having a burden of many years of prior therapy or fragility fractures became candidates for TPT. After 12 months, the anabolic window was revealed
by high bone remodelling blood markers, especially for osteocalcin.

Keywords: teriparatide, osteoporosis, fragility fracture

Full text | PDF

Leave a Reply